ASXL2 and neoplasm: The fact that loss of even a single copy of Asxl2 promoted leukemogenesis mediated by endogenous Aml1-Eto expression strongly supports the concept that Asxl2 is a haploinsufficient tumour suppressor in the context of this subtype of AML.